Provide report on stocks of rare genetic blood disorder injection: Delhi HC asks Centre, Delhi govt
New Delhi: In response to the plea filed by several individuals suffering from haemophilia disease, the Delhi High Court has directed the Centre and Delhi government to file their reports on the status of stocks of Antihemophilic Factor injection.
The governments have also been asked to also provide status reports on the existing supply chain system for all the hospitals under their administration. The court listed the matter on December 12, PTI reported.
Haemophilia is a rare genetic blood disorder that impairs the blood's ability to clot properly, leading to excessive bleeding even from minor injuries. It is caused by a deficiency in certain clotting factors, which are proteins that help blood clot. Hemophilia is inherited and is most commonly seen in males.
Read also: Plea for Urgent Financial Aid for Girl with Rare Disease: Delhi HC seeks Centre's reply
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.